Pharmaceutical

Oncoinvent’s Radspherin has FDA fast-track status for ovarian cancer

Oncoinvent has received FDA fast track designation for its therapy, Radspherin, to treat peritoneal metastases from ovarian cancer.

Jun 26, 2024 - 04:00
Oncoinvent’s Radspherin has FDA fast-track status for ovarian cancer
Oncoinvent has received FDA fast track designation for its therapy, Radspherin, to treat peritoneal metastases from ovarian cancer.
Read the original article

Tags:

Previous Article

Merck KGaA abandons Phase III trial for $1.08bn head & neck cancer drug

Next Article

Novavax seeks EMA approval for updated JN.1 Covid-19 vaccine

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Covid-19: Anti-inflammatory drugs do not lead to a swifter hospital exit

Covid-19: Anti-inflammatory drugs do not lead to a swif...

Jul 11, 2023

Labcorp forms spin-off of Fortrea

Labcorp forms spin-off of Fortrea

Jul 5, 2023

CDC advisory panel backs changes to Covid vaccination policy

CDC advisory panel backs changes to Covid vaccination p...

Apr 19, 2023